Lawmakers grill key fda official over controversial alzheimer’s drug approval
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
WASHINGTON — The Food and Drug Administration can’t escape questions about Aduhelm. Patrizia Cavazzoni, one of the agency’s highest-ranking drug regulators, set out to testify before
Congress Thursday on the intricacies of three looming funding bills crucial to the agency’s operations. But again and again, lawmakers grilled her about Biogen’s controversial Alzhiemer’s
drug. One lawmaker, Rep. Jan Schakowsky (D-Ill.), even joined the meeting just to chide Cavazzoni, even though she’s not a member of the subcommittee that held the hearing. STAT+ Exclusive
Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY INTELLIGENCE ON CAPITOL HILL AND THE LIFE SCIENCES INDUSTRY — BY
SUBSCRIBING TO STAT+. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe